News and Trends 16 Jun 2023 Flamingo Therapeutics receives €1.7M to advance RNA-targeting oncology portfolio Flamingo Therapeutics has been awarded a research grant of €1.7 million ($1.9 million) by Flanders Innovation & Entrepreneurship (VLAIO). The award represents the funding at 60% of a €2.9 million ($3.2 million) project. Funding from the grant will be used to advance Flamingo Therapeutics’ RNA-targeting oncology portfolio, including translational research for its lead clinical program, […] June 16, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2023 Finnish biotech startup Solu raises €1M to combat global antibiotic resistance Solu, founded in 2022, is a Finnish biotechnology company focusing on combating antibiotic resistance by building the world’s most extensive pathogen DNA library. Solu’s product makes understanding, detecting, and preventing the spread of antibiotic resistance easier and enables real-time monitoring to detect dangerous mutations effectively. The company has recently received seed funding of €1 million […] June 15, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jun 2023 Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases Beacon Therapeutics Holdings Limited has been launched to develop gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors including Oxford Science Enterprises, has provided £96 million ($120 million) to fund the acquisition of AGTC and provide capital to take Beacon Therapeutics’ development candidates […] June 12, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 6 Jun 2023 $5.5M funding for Oncopole to tackle cancer Oncopole, Fonds de recherche du Québec – Santé (FRQS) cancer division in Canada, has received major investments that boost its public-private partnership model dedicated to the fight against cancer. Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada. Oncopole, FRQS cancer division, is the result of […] June 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 5 Jun 2023 The biggest private biotech investments in May 2023 The companies ElevateBio, ReNAgade Therapeutics and Carmot Therapeutics bagged the biggest biotech investments in May 2023. Around the world, biomanufacturing and oncology players attracted the biggest funding rounds. A lot of private biotech fundraising took place in May 2023, with some particularly big rounds in the U.S. healthcare sector, as five companies took home $100 […] June 5, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2023 Anocca raises $36.6M for large-scale development of cancer cell therapies Anocca AB has raised SEK 400 million ($36.6 million) to further develop the discovery and manufacture of next generation cell therapies for cancer on an industrial scale. It will also allow Anocca to progress its first products into clinical trials. The financing brings together a group of existing and new investors, including Mellby Gård, AMF, […] June 2, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 ElevateBio raises $401M for cell and gene therapies ElevateBio, LLC (ElevateBio), a technology-driven company focused on cell and gene therapies, has closed its $401 million Series D financing. “We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company. We are thrilled to welcome Khalil to our […] June 1, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 UK invests £650M in life sciences A £650 million ($804 million) war-chest to boost the U.K.’s life sciences sector has been announced. The ‘Life Sci for Growth’ package brings together 10 different policies including £121 million ($150 million) to improve commercial clinical trials to bring new medicines to patients faster, up to £48 million ($59.4 million) of new money for scientific […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2023 VarmX raises €30M for blood clotting trial VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has successfully raised an additional €30 million ($32.2 million) in a Series B2 financing round. The round was led by Sound Bioventures while the European Innovation Council (EIC) Fund also joined as a new investor. Existing investors EQT Life […] May 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2023 PharmEnable raises $7.5M to develop small molecule drugs to treat cancer and neurological diseases PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi […] May 25, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2023 smartbax raises €1.2M to create next-generation antibiotics smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close of its seed financing round of €1.2 million ($1.3 million) from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF), bringing smartbax’s total capital raised to €1.9 million ($2.1 million). The funds will be used to advance smartbax’s small molecule […] May 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 AMR research gets £39m shot from UK government Research initiatives to develop new treatments to tackle antimicrobial resistance (AMR) – known as the “silent killer” – will receive a cash injection of up to £39 million ($48.5 million) from the U.K. government’s Global AMR Innovation Fund (GAMRIF). However, according to the director of Global Health Policy and Senior Policy Fellow at the Center […] May 23, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email